Switching of integrase inhibitors (dolutegravir, raltegravir and elvitegravir) due to adverse events to other antiretroviral treatments in patients with HIV infection: A three retrospective study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
Indications HIV infections
Focus Adverse reactions

30 Aug 2017 New trial record
26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com